The stock of Metagenomi Inc (MGX) has gone down by -6.53% for the week, with a -19.76% drop in the past month and a 36.68% rise in the past quarter. The volatility ratio for the week is 7.77%, and the volatility levels for the past 30 days are 11.05% for MGX. The simple moving average for the past 20 days is -19.59% for MGX’s stock, with a -33.23% simple moving average for the past 200 days.
Is It Worth Investing in Metagenomi Inc (NASDAQ: MGX) Right Now?
Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MGX is 18.78M and currently, short sellers hold a 10.89% of that float. On January 22, 2025, MGX’s average trading volume was 1.92M shares.
MGX) stock’s latest price update
Metagenomi Inc (NASDAQ: MGX) has seen a rise in its stock price by 4.21 in relation to its previous close of 2.61. However, the company has experienced a -6.53% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-16 that MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Approach On Track for One to Two Development Candidate Nominations in 2025 from Wave 1 Ionis Collaboration Programs Focusing on Cardiometabolic Indications Cash Runway Anticipated to Support Operating Plans into 2027 EMERYVILLE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today provided updates on the successful achievement of critical milestones across its therapeutic development programs and technology platforms in 2024 and anticipated milestones for 2025 and 2026.
Analysts’ Opinion of MGX
Many brokerage firms have already submitted their reports for MGX stocks, with H.C. Wainwright repeating the rating for MGX by listing it as a “Buy.” The predicted price for MGX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on May 07, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see MGX reach a price target of $6, previously predicting the price at $16. The rating they have provided for MGX stocks is “Neutral” according to the report published on May 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to MGX, setting the target price at $25 in the report published on March 05th of the previous year.
MGX Trading at -2.55% from the 50-Day Moving Average
After a stumble in the market that brought MGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.65% of loss for the given period.
Volatility was left at 11.05%, however, over the last 30 days, the volatility rate increased by 7.77%, as shares sank -12.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.91% upper at present.
During the last 5 trading sessions, MGX fell by -6.53%, which changed the moving average for the period of 200-days by -74.07% in comparison to the 20-day moving average, which settled at $3.38. In addition, Metagenomi Inc saw -24.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGX starting from Wapnick Pamela, who sale 1,559 shares at the price of $1.86 back on Dec 05 ’24. After this action, Wapnick Pamela now owns 61,492 shares of Metagenomi Inc, valued at $2,900 using the latest closing price.
Wapnick Pamela, the Chief Financial Officer of Metagenomi Inc, sale 6,265 shares at $2.88 during a trade that took place back on Sep 05 ’24, which means that Wapnick Pamela is holding 63,051 shares at $18,043 based on the most recent closing price.
Stock Fundamentals for MGX
Current profitability levels for the company are sitting at:
- -1.61 for the present operating margin
- 0.93 for the gross margin
The net margin for Metagenomi Inc stands at -1.34. The total capital return value is set at -0.28. Equity return is now at value -30.34, with -19.86 for asset returns.
Based on Metagenomi Inc (MGX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.24.
Currently, EBITDA for the company is -56.02 million with net debt to EBITDA at -0.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.23. The receivables turnover for the company is 93.51for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.18.
Conclusion
To wrap up, the performance of Metagenomi Inc (MGX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
